Directory of Services
Directory of Services of all diagnostic tests offered across our company’s portfolio.
OneCell Diagnostics is now 1Cell.Ai
Directory of Services of all diagnostic tests offered across our company’s portfolio.
The Jan 2026 edition of 1Cell.Ai Newsletter highlights key precision oncology trends including longitudinal liquid biopsy monitoring, clinical translation of
This edition highlights key advances in precision oncology from SABCS 2025, focusing on breast cancer, emerging biomarkers, AI-driven risk stratification,
Patient: 40 years – Female diagnosed with Renal cell carcinoma Clinical Testing: Treatment Options: The MSH6 gene mutation is indicative
Patient: 66 years – Male diagnosed with High grade urothelial papillary carcinoma Clinical Testing: Treatment Options: In general CDKN2A deficient
Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used
Patient: 69 years – Male diagnosed with Adenocarcinoma-Gallbladder Clinical Testing: Treatment Options: As per the NCCN recommendations ERBB2 mutations benefit
Patient: 54 years – Male diagnosed with Squamous cell carcinoma of Buccal Mucosa Clinical Testing: Treatment Options: Overall preclinical and
Patient: 52 years – Male diagnosed with Adenocarcinoma Lung with Brain metastasis Clinical Testing: Treatment Options: Osimertinib is standard of
Patient: 54 years – Female diagnosed with Recurrent Metastatic Ovarian Adenocarcinoma Clinical Testing: Treatment Options: Co-occurring mutations in BRAF and